Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Scandinavian Pharma Group ApS
APS
Bankrupt
CVR 42650668
Islands Brygge 108, st. th
Retail sale of cosmetic and toilet articles · NACE 4775
Est. 2021
— employees
Watchlist
Share
Download PDF
Full Risika report
Overview
Financials
People & ownership
Related companies
Revenue 2023
DKK -308K
+2459% vs 2022
EBITDA margin
102.7%
-2527% vs 2022
Equity ratio
-90.6%
Financial strength
Net profit 2023
DKK -247K
-1942% vs 2022
EBITDA — year on year
DKK millions
0M
0M
1M
1M
1M
0M
2022
0M
0%
2023
Key figures
Annual report 2023
Revenue
DKK -308K
+2459%
EBITDA
DKK -316K
-2527%
Net profit
DKK -247K
-1942%
Total assets
DKK 241K
+59%
Equity
DKK -219K
-883%
Employees
—
—
Company information
Legal name
Scandinavian Pharma Group ApS
CVR number
42650668
Legal form
Anpartsselskab
NACE code
4775 · Retail sale of cosmetic and toilet articles
Founded
1. september 2021
Share capital
DKK 40.002
Employees
—
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er salg af kosmetiske produkter og dermed beslægtet virksomhed
Contact
Address
Islands Brygge 108, st. th
Recent events
1 entries
Event
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Retail sale of cosmetic and toilet articles
Companies in København
All Denmark companies
Revenue
DKK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
EBITDA
DKK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
Income statement
DKK thousands
Item
2022
2023
Revenue
-12
-308
Staff expenses
-0
-8
EBITDA
-12
-316
Depreciation & amort.
-0
-0
EBIT
-12
-316
Net financials
-0
-2
Profit before tax
-12
-318
Tax
-0
-71
Net profit
-12
-247
Balance sheet
DKK thousands
Item
2022
2023
Total assets
151
241
Equity
28
-219
Long-term debt
0
0
Short-term debt
124
460
Total debt
124
460
Financial ratios
5-year trend
EBITDA margin
-31599900.0%
This company
15.8%
Market median
-199999467% vs market
2022
2023
Equity ratio
-90.6%
This company
38.2%
Market median
-337% vs market
2022
2023
Return on equity
-24663900.0%
This company
18.4%
Market median
-134043035% vs market
2022
2023
Net profit margin
-24663900.0%
This company
8.1%
Market median
-304492693% vs market
2022
2023
Asset turnover
-1.27×
This company
1.12×
Market median
-213% vs market
2022
2023
Debt / equity
2.10×
This company
0.62×
Market median
-239% vs market
2022
2023
Annual reports & filings
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2021-09-01 – 2022-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Age
Other directorships
HA
Helle Aakvist Jensen
Management
Management
2023
—
—
CR
Camilla Rude Bromark
Management
Management
2023
—
—
TM
Thomas Munkhøj Haslev
Unofficial title
Unofficial title
2025
—
—
NH
Nick Hielscher Abel
Chief Executive Officer
Chief Executive Officer
2023
—
—
Board of directors
Non-executive oversight
No data on file.
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
NA Invest ApS
Company
33.3%
33.3%
2023
By Sofus International Holding ApS
Company
33.3%
33.3%
2023
Camilla Rude Invest Holding ApS
Company
33.3%
33.3%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Camilla Rude Invest Holding ApS
Scandinavian Pharma Group ApS
(this company)
Board network connections
Board members of Scandinavian Pharma Group ApS also hold positions in
0
other companies.
Person
Role here
Other companies
Helle Aakvist Jensen
Management
0 companies
Camilla Rude Bromark
Management
0 companies
Thomas Munkhøj Haslev
Unofficial title
0 companies
Nick Hielscher Abel
Chief Executive Officer
0 companies